Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry | Zendy

Richard Cathomas | Zendy; Dirk Klingbiel | Zendy; Brandon Bernard | Zendy; Anja Lorch | Zendy; Xavier García del Muro | Zendy; Franco Morelli | Zendy; Ugo De Giorgi | Zendy; M. Fedyanin | Zendy; Christoph Oing | Zendy; Hege Sagstuen Haugnes | Zendy; Marcus Hentrich | Zendy; Christian D. Fankhauser | Zendy; Silke Gillessen | Zendy; J. Beyer | Zendy

Open Access

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry

Author(s) -

Richard Cathomas,

Dirk Klingbiel,

Brandon Bernard,

Anja Lorch,

Xavier García del Muro,

Franco Morelli,

Ugo De Giorgi,

M. Fedyanin,

Christoph Oing,

Hege Sagstuen Haugnes,

Marcus Hentrich,

Christian D. Fankhauser,

Silke Gillessen,

J. Beyer

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.00210

Subject(s) - medicine , seminoma , fluorodeoxyglucose , interquartile range , biopsy , positron emission tomography , radiology , chemotherapy , radiation therapy , nuclear medicine , surgery

FDG-PET has a low PPV for vital tumor in residual lesions after chemotherapy in patients with metastatic seminoma. This cautions against clinical decisions based on PET positivity alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research